Asahi Kasei

Mangrove Lithium, based in Vancouver, has developed a modular and scalable refining technology for the efficient production of battery-grade lithium hydroxide and carbonate from a variety of input streams. This innovative platform allows for the direct conversion of lithium chloride and lithium sulfate into high-quality lithium products. The technology can be adapted to different capacities and is designed to be co-located with upstream lithium producers, as well as cathode and cell manufacturers. Additionally, Mangrove’s platform is being commercialized for the conversion of waste brines into valuable chemicals and desalinated water, contributing to more sustainable practices in the lithium supply chain.

24M Technologies specializes in the development of energy storage systems for both grid and transportation applications. The company focuses on manufacturing lithium-ion batteries that enhance the operational reliability, economics, and efficiency of electric power systems. Its innovative approach features binder-free semisolid electrodes and unit cells, which not only improve battery performance but also eliminate the need for traditional hydro or pyrometallurgical processes in battery recycling. Additionally, 24M facilitates direct in-plant reuse of active materials at the end of a battery's life, contributing to more sustainable recycling practices and enabling clients to increase efficiency and reduce costs.

Calliditas Therapeutics AB, headquartered in Stockholm, Sweden, is a specialty pharmaceutical company dedicated to developing high-quality medicines for patients with significant unmet medical needs in niche indications. The company focuses on the development and commercialization of Nefecon (also known as TARPEYO), a unique formulation designed to treat IgA nephropathy (IgAN), an inflammatory renal disease. This patented, locally acting formulation combines a time lag effect with a concentrated release of budesonide within a designated target area. Calliditas is conducting a global Phase 3 study for Nefecon and aims to commercialize it in the United States.

Cyto-Facto is a biotechnology company specializing in the development and manufacturing of CAR-T cell therapies and mesenchymal stem cell products. It operates a research and development center dedicated to establishing quality standards for cell preparations used in gene and cell therapies. The company produces commercial CAR-T cell therapy products, including mesenchymal stem cells, and provides services such as management system development, sales support, and process development to help clients efficiently and reliably bring gene and cell therapies to patients.

Avation Medical, Inc. is focused on developing a non-invasive closed-loop neuromodulation system designed for the at-home treatment of overactive bladder. Established in 2016 and based in Columbus, Ohio, the company is pioneering wearable nerve stimulation platforms that emphasize patient empowerment and personalized care. By re-imagining neuromodulation through innovative, proven technologies, Avation Medical aims to enhance the management of chronic conditions, offering solutions that prioritize the needs and experiences of patients.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

LeadSound Technology researches battery non-destructive testing and monitoring technology. Their lithium-ion batteries are the technologies for the development of emerging industries such as renewable energy, energy vehicles, and information technologies. Their exploration of the health status and failure mechanism of lithium-ion batteries is bottlenecks restricting the development of battery technology, and lithium-ion batteries.

Ionomr Innovations Inc. is a Vancouver-based company specializing in the design, adaptation, and manufacture of advanced ion-exchange membranes and polymer technologies. Founded in 2013, Ionomr focuses on creating environmentally friendly materials that replace toxic fluorinated chemicals often used in electrochemical applications. Its flagship product line, Aemion, is designed for various applications, including water treatment, energy storage, and clean energy generation. The company’s innovative membranes are known for their alkaline stability, strength, and performance, enabling optimal integration into electrochemical systems. By providing solutions that enhance efficiency and reduce environmental impact, Ionomr aims to support the decarbonization of the planet and foster the development of sustainable systems in the renewable energy and circular chemical economies. Additionally, Ionomr offers chemical engineering services to further support its clients in achieving their operational goals.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

Natural Fiber Welding, Inc., founded in 2015 and based in Peoria, Illinois, specializes in the manufacturing and supply of sustainable fabrics and materials derived from plants. The company has developed a circularity platform that produces high-performance, plastic-free materials suitable for various industries, including fashion, footwear, automotive, and upholstery. By integrating its innovative technology into existing supply chains, Natural Fiber Welding enables brands to design and scale eco-friendly products effectively.

Castor Technologies, established in 2017 and based in Tel Aviv, Israel, specializes in 3D printing software solutions. The company connects manufacturers with 3D printing capabilities, aiding them in evaluating how to integrate industrial 3D printing into their production processes. Castor's proprietary technology offers a detailed technical and cost-saving assessment for an entire bill of materials, empowering designers, new product introduction managers, and production engineers to make informed decisions when manufacturing machine parts.

Curreio is a biotechnology company focused on drug discovery through advanced structural analysis using cryo-electron microscopy. The company offers a platform that enables researchers to observe biological structures in their native state by freezing them without staining. This innovative approach facilitates the discovery and analysis of potential life-saving drugs, leveraging structural analysis techniques to enhance the drug development process. By providing cutting-edge technology, Curreio aims to improve the efficiency and effectiveness of drug discovery efforts in the biotechnology sector.

iVexSol Inc. specializes in developing lentiviral vector manufacturing technology aimed at addressing the shortage of lentiviral vectors (LVVs), which are essential for gene therapy programs. Established in 2018 and based in Worcester, Massachusetts, the company offers a platform that produces a consistent supply of LVVs, critical for the manufacture of cell and gene therapies (CGTs). By utilizing banks of vector-producing cells, iVexSol's technology significantly increases production capacity while minimizing complexity and development time. This innovative approach not only reduces costs but also accelerates the clinical development timelines, ultimately enhancing patient access to life-saving treatments. The company’s solutions are designed to support researchers and manufacturers in the CGT field, facilitating the treatment of serious conditions such as late-stage cancers and genetic disorders.

Multus is a London-based company established in 2019 that specializes in providing affordable and efficient growth media for the cultivated meat industry. By employing a machine learning approach, Multus develops entirely animal-free growth media tailored specifically for animal cells, helping cultivated meat companies scale their production while maintaining high performance. The company focuses on optimizing growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the environmental drawbacks associated with traditional animal serum-based media. This innovative solution supports the growth of diverse animal cell types and tissues, enabling clients to produce sustainable meat products while minimizing the environmental and economic impacts of conventional meat production.

Plant Prefab specializes in custom construction services for single and multi-family homes, utilizing a patented prefabricated building system designed to enhance efficiency and sustainability. By employing advanced digital modeling and customizable Plant Panels and Modules, the company enables contractors and developers to accelerate the building process by 20 to 50 percent compared to traditional methods. This innovative system not only improves quality control but also offers greater design flexibility while reducing costs and material waste. Committed to sustainable practices, Plant Prefab has achieved carbon-neutral operations since 2020 and is recognized as the first housing prefabricator to pursue a net zero goal. The company aims to create healthier homes while minimizing the environmental impact of construction.

Circularise is a provider of digital product passports and mass balance bookkeeping software, focusing on sustainability and supply chain transparency. The company’s software assists suppliers, manufacturers, recyclers, and brands across various industries, including chemicals, plastics, battery materials, and metals, in tracing materials and sharing environmental data securely. Its primary offering, the digital product passport, provides detailed records of a product's origin, material composition, and environmental impact, supported by a blockchain-based chain of custody to ensure data security. This transparency allows companies to assess their Scope 3 emissions and align with emerging regulations related to climate risk disclosure and sustainability reporting. Additionally, Circularise offers tools for Life Cycle Assessments and calculating Product Carbon Footprints, aiding clients in establishing credible environmental impact records. The MassBalancer solution facilitates compliance with certifications, enabling efficient material management and sustainability declaration generation. With a focus on data privacy, Circularise's patented Smart Questioning feature empowers clients to control the sharing of sensitive information regarding sourcing, carbon footprints, and human rights issues, thereby minimizing manual errors and enhancing operational efficiency.

JustLight is a medical device company focused on developing innovative light-based technologies for health and wellness. Their primary products aim to treat joint and muscle pain through precise light wavelengths that promote healing and enhance cell function. Additionally, JustLight is exploring the potential of its technology for disinfecting surfaces and eliminating harmful pathogens. By utilizing photochemistry and biomechanics, the company has created skin-safe germicidal light that effectively sterilizes pathogens without the need for water or chemicals. Their patent-pending technology allows for automatic adjustments to the LED light output, ensuring that treatments are both effective and tailored to individual needs, providing users with the opportunity to manage their health in the comfort of their homes.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

OriCiro Genomics, Inc. is a biotechnology company based in Minato-ku, Japan, founded in 2018. It specializes in the research and development of innovative technologies for the cell-free synthesis and amplification of large DNA molecules. The company's core offerings include DNA assembly and circular DNA amplification technologies, which enable the construction of large circular DNA molecules without the need for traditional biological cloning methods. OriCiro Genomics aims to facilitate advancements in synthetic biology, providing its products to various sectors, including pharmaceuticals, diagnostics, food, and agriculture. By harnessing these technologies, the company seeks to contribute to a more efficient bioeconomy and promote new possibilities in gene therapy and related fields.

Bionova Scientific, Inc. is a biologics contract development and manufacturing organization based in Fremont, California, founded by a group of biopharmaceutical specialists in 2014. The company specializes in providing comprehensive services for biologics development and manufacturing, including early-stage research material generation, cell line development for new biological entities and biosimilars, and process development. Bionova Scientific supports the production of various biomolecules such as glycoproteins, monoclonal antibodies, and enzymes, focusing on optimizing expression systems and scaling up cell culture processes. Their expertise also extends to technology transfer and ensuring that biologic therapies are efficiently developed and brought to market for drug development companies.

Bionique Testing Laboratories, Inc. specializes in mycoplasma testing and consultation services tailored to meet the specific scientific and regulatory requirements of its clients. The company provides final drug product release testing in accordance with regulatory guidelines, utilizing a good manufacturing practices-compliant real-time PCR assay. This enables clients in the life sciences sector, including those involved in biopharmaceutical and cell therapy products, to navigate the entire process from concept to clinical trials and commercialization. Bionique Testing Laboratories aims to deliver high-quality mycoplasma testing products and services, establishing itself as a recognized global leader in the field.

Moment Energy focuses on developing sustainable battery energy storage systems that repurpose retired electric vehicle batteries. The company aims to enhance energy reliability for off-grid areas and address peak demand in on-grid locations. By utilizing these repurposed batteries, Moment Energy provides clean, reliable, and cost-effective energy storage solutions, making renewable energy more accessible for both off-grid and industrial customers.

HistoWiz, Inc. is a histology service company based in Brooklyn, New York, that specializes in processing, embedding, cutting, and staining mouse tissue specimens for cancer researchers in academia and the pharmaceutical industry. Founded in 2012, HistoWiz operates a fully automated histology laboratory and has developed an innovative online pathologist network. The company digitizes tissue samples and stores them in PathologyMap, its cloud database, which serves as a valuable resource for researchers. This platform not only facilitates rapid information exchange among medical scientists and research pathologists but also enhances data management and supports the integration of technology in pathology. By automating histopathology processes, HistoWiz aims to accelerate research and contribute to the discovery of new treatments for cancer.

Plant Prefab specializes in custom construction services for single and multi-family homes, utilizing a patented prefabricated building system designed to enhance efficiency and sustainability. By employing advanced digital modeling and customizable Plant Panels and Modules, the company enables contractors and developers to accelerate the building process by 20 to 50 percent compared to traditional methods. This innovative system not only improves quality control but also offers greater design flexibility while reducing costs and material waste. Committed to sustainable practices, Plant Prefab has achieved carbon-neutral operations since 2020 and is recognized as the first housing prefabricator to pursue a net zero goal. The company aims to create healthier homes while minimizing the environmental impact of construction.

Curreio is a biotechnology company focused on drug discovery through advanced structural analysis using cryo-electron microscopy. The company offers a platform that enables researchers to observe biological structures in their native state by freezing them without staining. This innovative approach facilitates the discovery and analysis of potential life-saving drugs, leveraging structural analysis techniques to enhance the drug development process. By providing cutting-edge technology, Curreio aims to improve the efficiency and effectiveness of drug discovery efforts in the biotechnology sector.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Super is an insurtech company that offers a subscription service for home care and repair.

SolidBlock Ltd is a company that offers a comprehensive platform designed for real estate developers and fund managers to facilitate fundraising through digital securities. Founded in 2018 and headquartered in Jerusalem, Israel, SolidBlock focuses on the intersection of finance and real estate, providing innovative solutions in tokenization and fintech. The platform enables users to efficiently connect with investors, streamlining the process of raising capital for various real estate projects.

PeptiStar Inc., founded in 2017 and headquartered in Osaka, Japan, specializes in the development and manufacturing of peptide medicines. As a Contract Development and Manufacturing Organization (CDMO), PeptiStar offers a range of services for peptide active pharmaceutical ingredients (APIs), including traditional and advanced forms such as macrocyclic and stapled peptides that incorporate non-natural amino acids. The company focuses on innovative manufacturing technologies to enhance the efficiency and effectiveness of peptide therapeutics, thereby supporting the pharmaceutical industry in accelerating drug development. Through its commitment to open innovation, PeptiStar aims to deliver high value-added services to its clients, contributing significantly to advancements in peptide medicine.

Everactive, Inc., also known as Everactive Insights, Inc., specializes in the development of wireless sensing devices and technologies tailored for Industrial Internet of Things (IoT) applications. The company produces ultra-low-power chips that enable battery-less wireless sensors, facilitating data generation and analytics for various industrial operations. Its innovations include PsiKick integrated circuits, which support programmable processing, power management, and RF communication. Everactive's solutions encompass steam trap monitoring, flare system monitoring, and machine health monitoring, allowing for continuous analysis of industrial assets. Founded in 2012 and headquartered in Santa Clara, California, Everactive also has locations in Charlottesville, Virginia, and Ann Arbor, Michigan. The company’s technology is based on energy harvesting, enabling low-cost and long-lived instrumentation that supports sustainable and scalable IoT applications.

Aryballe Technologies, established in 2014 and headquartered in Grenoble, France, specializes in developing sensors and software that mimic the human sense of smell. Their core products include eNose, O-Cell, NeOse Pro, and Solgel, which use biochemistry, optics, and machine learning to identify, measure, and represent odors. These solutions are designed for various industries such as food and beverage, cosmetics, and automotive, aiding in research, quality control, and end-user experiences.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

UltraSense Systems, Inc. develops integrated 3D ultrasound sensor solutions aimed at enhancing user interaction with technology. The company offers TouchPoint sensors that enable low-power user interfaces capable of detecting touch and force through various materials and thicknesses using its patented 3D ultrasound technology. These sensors are applicable across multiple sectors, including smartphones, consumer electronics, home appliances, automotive, industrial, and medical markets, allowing for precise and localized buttonless interfaces. Founded in 2017 and headquartered in San Jose, California, UltraSense Systems also provides a development kit to facilitate the integration of its technology. Products are distributed through various channels, making them accessible for a wide array of applications.

Veloxis is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. Envarsus® is a once-daily dosage version of tacrolimus, the market-leading primary immunosuppressant in the transplant market, and has successfully demonstrated non-inferiority compared to Prograf® in its two Phase III clinical trials, Study 3001 (stable kidney transplant patients) and Study 3002 (de novo kidney transplant patients). In April 2013, the company submitted a marketing authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. In December 2013, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and enrolled over 1000 patients, including two pivotal clinical trials, studies 3001 and 3002. At the same time, Envarsus® was granted Orphan Drug status by the FDA for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The company is using its proprietary MeltDose technology in the formulation of Envarsus® to enhance the bioavailability of the drug and allow for a sustained or modified release plasma profile. The MeltDose technology has been validated in clinical studies through FDA approval of Fenoglide (now on the market) for the treatment of dyslipidemia in adults. Veloxis was founded in June 2002 as a spin-off from H. Lundbeck A/S and is listed on NASDAQ OMX Copenhagen A/S (OMX: VELO). Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in New Jersey, U.S.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, producing high-performance measurement systems that utilize multi-path scattered field theory. Integral Geometry Science is particularly noted for its microwave mammography system, which addresses challenges in imaging high-density breast tissue. This innovative technology improves the clarity of images, allowing for accurate differentiation between cancerous and normal tissue, thus reducing the need for painful and radiation-exposing conventional screening methods. Additionally, the company manufactures nondestructive inspection systems for lithium-ion batteries, contributing to safety and reliability in battery technology.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Laminate Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, founded in 2012. The company focuses on improving vascular access for hemodialysis patients through its innovative product, the VasQ device. This implanted blood vessel external support device is designed to be used during the creation of arteriovenous fistulas, addressing issues such as wall tension and undesired narrowing of veins that can lead to complications within the first year. By enhancing the geometry of the fistula and reducing the risk of blockages, VasQ aims to significantly lower the annual fistula failure rate. This advancement seeks to transform the treatment landscape for hemodialysis patients, minimizing kidney-failure related complications and the associated costs of re-interventions and vascular access complications.

SAGE Automotive Interiors, Inc. specializes in designing, developing, and manufacturing innovative automotive interior solutions for various vehicle types, including cars, trucks, and SUVs. The company produces interior fabrics utilized in seating, headliners, door panels, and consoles, catering to the needs of automotive manufacturers globally. Established in 2009 and headquartered in Greenville, South Carolina, SAGE operates additional facilities in North America, Brazil, China, Europe, India, Japan, Korea, and Thailand. Known for its cutting-edge design and engineering capabilities, the company maintains a strong commitment to quality and service. As a subsidiary of Asahi Kasei Corporation, SAGE Automotive Interiors continues to enhance its reputation by providing advanced-performance specialty fabric materials at competitive prices, ensuring it meets the evolving demands of the automotive industry.

Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients suffering from severe infections and acute inflammatory conditions. Atox Bio focuses on novel therapies that target multiple pathways within both the adaptive and innate immune responses, which are crucial in managing infectious diseases, inflammatory disorders, and ischemia/reperfusion injuries. The company’s products are designed to address serious medical conditions with high morbidity and mortality, showing promising results in improving patient outcomes and reducing tissue damage during acute inflammatory events.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Aryballe Technologies, established in 2014 and headquartered in Grenoble, France, specializes in developing sensors and software that mimic the human sense of smell. Their core products include eNose, O-Cell, NeOse Pro, and Solgel, which use biochemistry, optics, and machine learning to identify, measure, and represent odors. These solutions are designed for various industries such as food and beverage, cosmetics, and automotive, aiding in research, quality control, and end-user experiences.

Arcterus Co., Ltd. is a company based in Setagaya-Ku, Japan, founded in 2010. It specializes in developing a digital notebook application designed for students to upload and share class notes, enhancing their learning experience. The application also includes assessment tools tailored for both teachers and students, facilitating a more interactive educational environment. Additionally, Arcterus operates a tutoring center, further supporting students in their academic pursuits. The company's approach incorporates adaptive learning techniques to optimize the educational experience based on individual learning styles, leveraging technology and big data to provide personalized guidance and support.

Axine Water Technologies Inc. is a Vancouver-based company specializing in innovative wastewater treatment solutions. Established in 2010, it focuses on developing chemical-free systems that effectively treat high concentrations of complex, toxic organics and ammonia found in industrial wastewater. Utilizing a proprietary electrolytic oxidation technology, Axine's systems can address a broad range of pollutants, including phenols, pharmaceuticals, dioxins, and various organic compounds, without generating sludge or requiring chemical additives. The company aims to provide cost-effective and energy-efficient alternatives to traditional wastewater treatment methods, catering to industries such as oil and gas, petrochemicals, pharmaceuticals, textiles, and waste management. Its solutions enable both industrial and municipal clients to enhance the performance and reduce the costs of their wastewater treatment processes.

Mirexus Inc. is a Canadian company based in Guelph that specializes in developing sustainable nanoparticles for various applications, including personal care, nutraceuticals, specialty foods, and pharmaceuticals. Founded in 2008, the company commercializes PHYTOSPHERIX, a natural biopolymer identical to glycogen, which enhances the formulation of longer-lasting personal care products and improves the shelf life of specialty materials. The versatile technology, derived from research at the University of Guelph, enables the development of products such as moisturizers, sunscreens, hyaluronic acid replacements, dermal fillers, dry color cosmetics, and hair conditioners. Mirexus Inc. is actively pursuing partnerships with industry stakeholders to create innovative solutions utilizing its unique technology.

Polypore International specializes in the development, manufacturing, and marketing of polymer-based microporous membranes utilized in various separation and filtration processes. The company boasts a diverse portfolio that includes polypropylene and polyethylene monolayer and multilayer membrane separators specifically designed for lithium batteries, which are integral to consumer electronics like mobile phones, laptops, and power tools. Additionally, Polypore’s separation media segment offers membranes and modules for healthcare, industrial, and specialty filtration applications. The company's growth is driven by rising global demands for portable energy solutions and the need for high-performance filtration to ensure product purity.

ZOLL Medical Corporation, a subsidiary of the Asahi Kasei Group, specializes in the development and marketing of medical devices and software solutions designed to enhance emergency care and improve the efficiency of clinical operations. The company’s product range includes defibrillators, patient monitors, CPR feedback systems, data management software, fluid resuscitation tools, and therapeutic temperature management devices. ZOLL's technologies support a wide array of users, including clinicians, emergency medical services (EMS), fire professionals, and lay rescuers, enabling them to effectively treat patients requiring resuscitation and acute critical care. By providing comprehensive solutions, ZOLL aims to advance the standards of emergency medical services and ultimately save lives.

Crystal IS specializes in the production of ultraviolet light emitting diodes (UV LEDs) utilizing single-crystal aluminum nitride (AlN) substrate technology. As a leader in this field, the company focuses on creating high-performance UVC LEDs designed for water, surface, and air purification applications. Their products cater to a wide range of sectors, including consumer and commercial appliances, medical devices, and life sciences. By emphasizing energy efficiency and durability, Crystal IS enables its clients to enhance their production with effective disinfection solutions.

Envia Systems specializes in developing advanced lithium-ion batteries that offer high energy density at a lower cost. By combining innovative high-energy electrodes, the company produces batteries suitable for clean energy applications, including electric vehicles, hybrid electric vehicles, and plug-in hybrid electric vehicles. Their technology aims to enhance the performance of energy storage solutions, facilitating the broader adoption of sustainable energy systems.

Crystal IS specializes in the production of ultraviolet light emitting diodes (UV LEDs) utilizing single-crystal aluminum nitride (AlN) substrate technology. As a leader in this field, the company focuses on creating high-performance UVC LEDs designed for water, surface, and air purification applications. Their products cater to a wide range of sectors, including consumer and commercial appliances, medical devices, and life sciences. By emphasizing energy efficiency and durability, Crystal IS enables its clients to enhance their production with effective disinfection solutions.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.